Bulk Pharmaceutical API Sources for remimazolam besylate

Bulk Pharmaceutical API Sources for remimazolam besylate

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-14867A
AbaChemScene		CS-5316
AbovChem LLC		HY-14867A
Acorn PharmaTech Product List		ACN-049984

REMIMABOLAM BESYLATE BULK ACTIVE PHARMACEUTICAL INGREDIENT (API) SOURCES

Last updated: February 19, 2026

This report details current and potential sources for the bulk Active Pharmaceutical Ingredient (API) Remimazolam Besylate. It covers manufacturing capabilities, patent landscapes impacting API production, and regulatory considerations for commercial supply.

What is Remimazolam Besylate?

Remimazolam Besylate is an ultra-short-acting intravenous benzodiazepine sedative. It is metabolized by tissue esterases, leading to rapid onset and offset of sedation. Its primary indication is for procedural sedation. The besylate salt form offers improved solubility and stability compared to the free base.

Key API Manufacturers and Suppliers

Commercial production of Remimazolam Besylate API is concentrated among a limited number of specialized pharmaceutical manufacturers. These entities possess the necessary chemical synthesis expertise and quality control systems to meet stringent pharmaceutical standards.

Primary API Manufacturers:

• Piramal Pharma Solutions: This company is a significant player in the contract development and manufacturing organization (CDMO) space and has been identified as a key supplier for Remimazolam Besylate API. They operate multiple sites with cGMP capabilities, including facilities in India and North America. Their expertise spans complex multi-step synthesis and scale-up for commercial quantities. (Source: Industry reports, company press releases)
• ASKA Pharmaceutical Co., Ltd.: As the originator company for remimazolam (marketed as Byfavo® in some regions), ASKA Pharmaceutical likely maintains internal API manufacturing capabilities or closely manages its supply chain. ASKA Pharmaceutical is a Japanese pharmaceutical company focused on anesthetics, critical care, and urology. (Source: Company annual reports, regulatory filings)
• WuXi AppTec: This global pharmaceutical and medical device outsourcing company has extensive API development and manufacturing services. While specific confirmation for remimazolam besylate API production may not be publicly disclosed, their broad capabilities make them a potential supplier for such complex molecules. They operate cGMP facilities in China and the United States. (Source: Company service offerings)

Secondary and Emerging Suppliers:

The landscape of API suppliers for newer molecules like remimazolam besylate is dynamic. As patent exclusivity for originator products wanes or as demand increases, additional manufacturers, particularly in India and China, are likely to develop and offer the API. These may include:

• Specialized API Manufacturers: Companies focusing on niche therapeutic areas or complex chemical synthesis.
• Generic Drug Manufacturers: Post-patent expiry, generic API producers will enter the market.

Identifying these emerging suppliers typically requires detailed market intelligence and direct engagement with potential vendors.

Patent Landscape Impacting API Production

The patent portfolio surrounding Remimazolam Besylate significantly influences API manufacturing and market entry. Key patents relate to the compound itself, its salt forms, synthesis processes, and specific formulations.

Composition of Matter Patents:

The fundamental patent protecting remimazolam as a novel chemical entity is critical. Patents covering the free base and specific salt forms, such as the besylate, dictate the earliest potential for generic API production.

• Exclusivity Periods: Originator companies hold patents that grant them market exclusivity for a defined period. For remimazolam, these patents are based on its discovery and development.
• Patent Expiry: The expiration dates of key composition of matter patents are crucial for determining when generic API manufacturers can legally produce and sell remimazolam besylate API without infringing on the originator's core intellectual property. Specific expiry dates are subject to regional patent law and potential extensions (e.g., patent term extensions in the US and EU).

Process Patents:

Patents protecting specific synthetic routes to remimazolam besylate are also vital.

• Novel Synthesis Methods: Innovator companies often patent unique or improved methods for synthesizing the API. These patents can prevent competitors from using the same efficient or cost-effective manufacturing processes, even if the composition of matter patent has expired.
• Freedom to Operate (FTO): API manufacturers must conduct thorough FTO analyses to ensure their chosen synthesis routes do not infringe on existing process patents. This can lead to the development of alternative, non-infringing synthetic pathways.
• Examples of Process Patent Considerations:
  • Patents on specific chiral resolution techniques.
  • Patents on novel coupling reactions or purification methods.
  • Patents on intermediate compounds used in the synthesis.

Salt Form Patents:

Patents specifically claiming the besylate salt of remimazolam are important.

• Improved Properties: Besylate salts are often chosen for their enhanced solubility, stability, or manufacturability. Patents protecting these specific salt forms prevent others from producing the besylate form directly.
• Alternative Salts: If the besylate salt is heavily patented, alternative salt forms of remimazolam may be explored for generic development, provided they offer comparable therapeutic or manufacturing benefits and are not themselves covered by patents.

Formulation and Use Patents:

While primarily affecting finished drug products, patents related to specific formulations or methods of use can indirectly impact API demand.

• Combination Therapies: Patents on using remimazolam in combination with other agents.
• Specific Dosage Forms: Patents on particular delivery devices or fixed-dose combinations.

Implications for API Sourcing:

• Originator Control: During the primary patent exclusivity period, the originator company or its designated CDMOs are the primary, if not sole, legal sources for the API.
• Generic Entry: Post-patent expiry for core patents, generic API manufacturers can enter the market. However, they must navigate process and salt form patents.
• Cost and Competition: The number of FTO-compliant synthesis routes available will influence the number of generic API suppliers, impacting pricing and competition.
• Regulatory Filings: API manufacturers intending to supply generic drug makers must file Drug Master Files (DMFs) or equivalent regulatory submissions with health authorities (e.g., FDA, EMA) to demonstrate the quality and consistency of their API production.

A comprehensive patent landscape analysis, including freedom-to-operate opinions, is essential for any company looking to develop or procure Remimazolam Besylate API for commercial purposes.

Regulatory Considerations for API Supply

Sourcing bulk Remimazolam Besylate API requires strict adherence to pharmaceutical regulations to ensure product quality, safety, and efficacy. Regulatory oversight is managed by national and international health authorities.

Current Good Manufacturing Practices (cGMP):

• Mandatory Compliance: All API manufacturers must comply with cGMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
• Key cGMP Elements:
  • Quality Management System: Robust systems for documentation, change control, deviation management, and CAPA (Corrective and Preventive Actions).
  • Facility and Equipment: Properly designed, maintained, and validated manufacturing facilities and equipment.
  • Personnel: Qualified and trained personnel.
  • Material Control: Strict control over raw materials, intermediates, and finished API.
  • Process Validation: Demonstrating that the manufacturing process consistently produces API meeting pre-determined specifications.
  • Analytical Testing: Validated methods for testing raw materials, in-process samples, and finished API to ensure identity, strength, quality, and purity.
  • Stability Testing: Data demonstrating the API's shelf life under specified storage conditions.

Drug Master Files (DMFs):

• API Manufacturer Submissions: API manufacturers typically submit a DMF to regulatory agencies. A DMF contains confidential, detailed information about the API manufacturing process, facilities, and quality controls.
• Drug Product Manufacturer Reference: Finished drug product manufacturers reference the API manufacturer's DMF in their marketing applications (e.g., New Drug Application - NDA, Abbreviated New Drug Application - ANDA).
• Confidentiality: The DMF allows regulatory agencies to review the API's manufacturing details without the API manufacturer having to disclose proprietary information directly to the drug product manufacturer.

Inspections and Audits:

• Regulatory Inspections: Health authorities conduct routine inspections of API manufacturing facilities to verify cGMP compliance.
• Customer Audits: Drug product manufacturers routinely audit their API suppliers to ensure quality and compliance before and during the commercial supply agreement. These audits often focus on specific aspects of the manufacturing process and quality systems relevant to their finished product.

International Standards:

• ICH Guidelines: Manufacturers often follow International Council for Harmonisation (ICH) guidelines, which provide recommendations on quality, safety, efficacy, and multidisciplinary topics for pharmaceutical development and registration. Key ICH guidelines for API manufacturing include ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients).

Supply Chain Security and Traceability:

• Counterfeit Prevention: Ensuring the authenticity and integrity of the API throughout the supply chain is paramount. This involves robust serialization and tracking systems.
• Ethical Sourcing: Ensuring raw materials are sourced ethically and responsibly.

Specific Considerations for Remimazolam Besylate API:

• Impurity Profiling: Identifying, quantifying, and controlling process-related impurities and degradation products is critical. This includes genotoxic impurities.
• Chiral Purity: As remimazolam is a chiral molecule, ensuring high enantiomeric purity is essential for therapeutic efficacy and safety.
• Salt Form Consistency: Ensuring consistent crystalline form and particle size distribution of the besylate salt is important for downstream formulation.

Compliance with these regulatory requirements is non-negotiable for any API supplier seeking to enter or maintain a position in the Remimazolam Besylate market.

API Sourcing Strategy Considerations

Developing a robust sourcing strategy for Remimazolam Besylate API requires a multi-faceted approach, balancing supply security, cost-effectiveness, and regulatory compliance.

Key Strategic Elements:

1. Supplier Qualification and Due Diligence:

   • Technical Capability: Assess manufacturing expertise, scalability, and experience with similar complex syntheses.
   • Quality Systems: Evaluate cGMP compliance through audits, review of quality agreements, and historical inspection records.
   • Regulatory Standing: Confirm DMF filings and regulatory approval history in target markets.
   • Financial Stability: Assess the supplier's financial health to ensure long-term supply reliability.
   • Intellectual Property (IP) Assessment: Verify freedom to operate for the chosen synthesis route and confirm no undisclosed IP encumbrances.

2. Supply Chain Risk Mitigation:

   • Dual Sourcing: Identify and qualify at least two independent API suppliers to mitigate risks associated with single-source dependency (e.g., manufacturing disruptions, geopolitical issues, quality failures).
   • Geographic Diversification: Consider suppliers in different geographic regions to reduce exposure to localized risks.
   • Inventory Management: Establish appropriate safety stock levels for API based on lead times and demand variability.

3. Cost Optimization:

   • Negotiation Leverage: A competitive supplier landscape provides opportunities for favorable pricing.
   • Long-Term Contracts: Secure competitive pricing and supply commitments through multi-year agreements.
   • Process Efficiency: Collaborate with API manufacturers to identify opportunities for process improvements that reduce manufacturing costs without compromising quality.

4. Technical Collaboration and Support:

   • Process Transfer: For new entrants or second-source development, ensure seamless technology transfer and process validation.
   • Troubleshooting: Establish clear communication channels for rapid resolution of any technical or quality issues.
   • Continuous Improvement: Work with suppliers on ongoing efforts to optimize yield, purity, and reduce waste.

5. Regulatory Readiness:

   • DMF Support: Ensure API suppliers have robust DMFs and are prepared to provide necessary support for your drug product regulatory submissions.
   • Change Control: Implement rigorous change control processes with suppliers to manage any modifications to the manufacturing process or specifications that could impact the finished drug product.

Example Sourcing Scenarios:

• Scenario A: Early-Stage Development (Pre-Launch): Focus on CDMOs with strong development capabilities (e.g., Piramal Pharma Solutions, WuXi AppTec) for initial scale-up and validation batches. Prioritize technical expertise and rapid development timelines. Establish a second potential supplier for future commercialization.
• Scenario B: Commercial Supply (Post-Patent Expiry): Engage with multiple qualified API manufacturers (potentially including those in India and China who have developed FTO-compliant processes) to foster competition and ensure supply security. Conduct thorough due diligence on all potential suppliers, paying close attention to cGMP compliance and regulatory filings.

A proactive and strategic approach to API sourcing is critical for ensuring the reliable and cost-effective supply of Remimazolam Besylate for pharmaceutical products.

Key Takeaways

• Commercial Remimazolam Besylate API supply is currently dominated by specialized CDMOs and the originator.
• Key API manufacturers include Piramal Pharma Solutions and ASKA Pharmaceutical Co., Ltd., with WuXi AppTec as a potential supplier.
• The patent landscape, encompassing composition of matter, process, and salt form patents, significantly dictates market entry for API manufacturers.
• Strict adherence to cGMP, robust DMFs, and regulatory inspections are essential for API suppliers.
• A dual-sourcing strategy and thorough supplier due diligence are critical for mitigating supply chain risks and ensuring quality.

Frequently Asked Questions

1. What is the typical lead time for sourcing bulk Remimazolam Besylate API from qualified manufacturers? Lead times can vary significantly based on supplier capacity, existing production schedules, and order volume, but typically range from 3 to 9 months from order placement to delivery for established commercial supply agreements.

2. Are there any known significant impurities associated with Remimazolam Besylate API that manufacturers must control? Manufacturers must control process-related impurities arising from synthesis steps and potential degradation products. Specific impurity profiles are detailed in regulatory filings and are subject to pharmacopoeial standards and ICH guidelines.

3. What is the role of regulatory bodies like the FDA and EMA in approving API suppliers for Remimazolam Besylate? These bodies do not directly approve individual API suppliers. Instead, they review the API information submitted within a drug product manufacturer's marketing application (e.g., through referenced DMFs) and inspect manufacturing facilities for cGMP compliance.

4. Can generic API manufacturers produce Remimazolam Besylate API before the originator's key patents expire? Generic manufacturers can only legally produce and sell the API if their synthesis routes and product do not infringe on any valid and in-force patents, including composition of matter, process, and salt form patents held by the originator or other entities.

5. What are the implications of supply chain disruptions for Remimazolam Besylate API? Disruptions can lead to drug product shortages, increased costs due to expedited shipping or alternative sourcing, and delays in market supply. Dual sourcing and robust inventory management are primary strategies to mitigate these risks.

---

Citations

[1] ASKA Pharmaceutical Co., Ltd. (n.d.). Company Overview. Retrieved from [Company website - specific page not provided as it is general company information] [2] Piramal Pharma Solutions. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company website - specific page not provided as it is general company information] [3] WuXi AppTec. (n.d.). API Development & Manufacturing. Retrieved from [Company website - specific page not provided as it is general company information] [4] U.S. Food and Drug Administration. (2023). Guidance for Industry: Drug Master Files. Retrieved from [FDA website] [5] European Medicines Agency. (n.d.). Active substances (APIs). Retrieved from [EMA website] [6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website]